Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2004 2
2007 1
2008 2
2009 3
2010 1
2011 6
2012 6
2013 3
2014 7
2015 2
2016 1
2017 4
2018 4
2019 2
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

42 results
Results by year
Filters applied: . Clear all
Page 1
Mitf is a master regulator of the v-ATPase, forming a control module for cellular homeostasis with v-ATPase and TORC1.
Zhang T, Zhou Q, Ogmundsdottir MH, Möller K, Siddaway R, Larue L, Hsing M, Kong SW, Goding CR, Palsson A, Steingrimsson E, Pignoni F. Zhang T, et al. Among authors: Hsing M. J Cell Sci. 2015 Aug 1;128(15):2938-50. doi: 10.1242/jcs.173807. Epub 2015 Jun 19. J Cell Sci. 2015. PMID: 26092939 Free PMC article.
ETS transcription factors as emerging drug targets in cancer.
Hsing M, Wang Y, Rennie PS, Cox ME, Cherkasov A. Hsing M, et al. Med Res Rev. 2020 Jan;40(1):413-430. doi: 10.1002/med.21575. Epub 2019 Mar 29. Med Res Rev. 2020. PMID: 30927317 Review.
Local hemostatic matrix for endoscope-assisted removal of intracerebral hemorrhage is safe and effective.
Luh HT, Huang AP, Yang SH, Chen CM, Cho DY, Chen CC, Kuo LT, Li CH, Wang KC, Tseng WL, Hsing MT, Yang BS, Lai DM, Tsai JC. Luh HT, et al. Among authors: Hsing MT. J Formos Med Assoc. 2018 Jan;117(1):63-70. doi: 10.1016/j.jfma.2017.02.016. Epub 2017 Mar 23. J Formos Med Assoc. 2018. PMID: 28343893 Free article. Clinical Trial.
Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner.
Tam KJ, Dalal K, Hsing M, Cheng CW, Khosravi S, Yenki P, Tse C, Peacock JW, Sharma A, Chiang YT, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Tam KJ, et al. Among authors: Hsing M. Oncotarget. 2017 Feb 7;8(6):9617-9633. doi: 10.18632/oncotarget.14168. Oncotarget. 2017. PMID: 28038451 Free PMC article.
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.
Butler MS, Roshan-Moniri M, Hsing M, Lau D, Kim A, Yen P, Mroczek M, Nouri M, Lien S, Axerio-Cilies P, Dalal K, Yau C, Ghaidi F, Guo Y, Yamazaki T, Lawn S, Gleave ME, Gregory-Evans CY, McIntosh LP, Cox ME, Rennie PS, Cherkasov A. Butler MS, et al. Among authors: Hsing M. Oncotarget. 2017 Jun 27;8(26):42438-42454. doi: 10.18632/oncotarget.17124. Oncotarget. 2017. PMID: 28465491 Free PMC article.
Identification of a potent antiandrogen that targets the BF3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer.
Munuganti RS, Hassona MD, Leblanc E, Frewin K, Singh K, Ma D, Ban F, Hsing M, Adomat H, Lallous N, Andre C, Jonadass JP, Zoubeidi A, Young RN, Guns ET, Rennie PS, Cherkasov A. Munuganti RS, et al. Among authors: Hsing M. Chem Biol. 2014 Nov 20;21(11):1476-85. doi: 10.1016/j.chembiol.2014.09.012. Chem Biol. 2014. PMID: 25459660 Free article.
42 results
Jump to page
Feedback